Anthem Biosciences block deal: ₹1,275 crore stake sale

Deal snapshot: promoter stake changes hands

Global financial institutions and Indian institutional investors bought a 3.05% stake in Anthem Biosciences in a large block deal worth about ₹1,275 crore. The stake was sold by promoter Aruna Ganesh through open market transactions on the National Stock Exchange (NSE), according to block deal data. The trade involved 1,71,14,604 shares changing hands at an average price of ₹744.80 per share. The aggregate transaction value was ₹1,274.69 crore. After selling an equal number of shares, Ganesh exited the company.

The deal mattered because it brought a mix of well-known global investors and domestic mutual funds into the stock in one go. It also reduced the promoters’ overall holding, a key datapoint that market participants track closely after large secondary trades. The transaction took place on June 18, with market attention rising after reports highlighted the planned sale and the floor price.

What exactly happened on the NSE

Block deal data showed multiple investors buying shares on Thursday, together representing 3.05% of the company. The average deal price of ₹744.80 was below the stock’s prevailing levels during the session, reflecting how block trades are often executed at a negotiated price.

According to sources cited in the report, the floor price for the transaction was set at ₹715 per share. This was described as roughly 7% below the previous day’s closing price. The trade did not involve any issuance of new shares, meaning the company’s equity base did not change as a result of this transaction.

Key buyers: global institutions and Indian funds

The institutional demand came from both overseas and domestic pools of capital. The global participants included Societe Generale, Prudential Hong Kong and Ghisallo Capital Management. Other foreign investors in the deal included Luxembourg-based Nordea Asset Management, Integrated Core Strategies Asia Pte Ltd and Social Protection Fund.

On the domestic side, several mutual funds participated, including SBI Mutual Fund, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, UTI Mutual Fund, Edelweiss Mutual Fund, Canara Robeco Mutual Fund, 360 ONE Mutual Fund, Mahindra Manulife Mutual Fund, and WhiteOak Capital Mutual Fund. Other domestic institutional buyers listed in the data included PI Opportunities AIF V LLP (an affiliate of Premji Invest), Kotak Mahindra Life Insurance Company, Bajaj Life Insurance, and ICICI Prudential Life Insurance.

Stock price reaction during and after the deal

Price action around the deal was mixed across different snapshots reported through the day. After the transaction, Anthem Biosciences was reported trading flat at ₹798.25 per share on the NSE. Another update noted that the stock surged to a day high of ₹811 on June 18 after the pre-market block deal worth nearly ₹1,275 crore.

At 10:07 am on the NSE, the stock was reported up 3.80% at ₹796.65. By close, the stock was cited at ₹799.80, nearly 4% higher. Separately, a later datapoint stated that as of 19-06-2026, the share price was ₹798.10 with a previous close of ₹798.10.

Promoter holding falls after Aruna Ganesh exits

The stake sale had a direct impact on the promoter shareholding pattern. Following the transaction, the combined holding of promoters and promoter group entities in Anthem Biosciences declined to 71.63% from 74.68%.

Aruna Ganesh sold the same number of shares that the institutions bought and exited the company. The reduction in promoter holding is mechanical in this case, driven by the sale, and does not by itself indicate a change in the company’s operations.

Understanding block deals and why they matter

A block deal is a large, pre-arranged trade executed on the stock exchange, typically between a seller such as a promoter or a large shareholder and institutional buyers. In this case, the transaction involved secondary shares being transferred, not a fresh issue. As the report noted, such a block deal does not create new shares and does not alter business operations.

For markets, block deals are watched for the quality of buyers, the discount to market price, and any subsequent change in promoter holdings. The participation of multiple mutual funds and insurers usually signals that there was enough institutional appetite to absorb the large supply in one session.

Company profile: pharma services focus

Anthem Biosciences is described as a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO). Companies in this segment provide research and manufacturing services to pharmaceutical and biotech clients, making them part of the broader pharma services ecosystem.

The investor mix in the deal included global institutions and a broad set of Indian mutual funds, reinforcing that the stock is actively tracked by both foreign and domestic institutions.

Corporate actions and key stock metrics cited

Apart from the block deal, the company had announced a dividend of ₹2 per share with an ex-date of 25 June 2026. The stock was also reported to have gained nearly 25% so far this year.

The same report cited a 52-week high of ₹873.50 and a 52-week low of ₹579.15, providing context on where the stock traded relative to its recent range.

Earlier institutional activity: anchor book and IPO details cited

A separate update in the provided material said Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors via its anchor book on July 11. The company said it finalised allocation of 1.78 crore equity shares to anchor investors at a price of ₹570 per share.

That update also mentioned the company was raising ₹3,395 crore via an initial share sale comprising entirely an offer-for-sale by existing shareholders, including investors Viridity Tone and Portsmouth Technologies. The same section listed several global and domestic investors participating via the anchor book.

Key numbers at a glance

What investors will track next

After a large promoter sell-down, investors typically monitor subsequent shareholding disclosures and whether any further block trades emerge. In the near term, attention is also likely to remain on the dividend ex-date of 25 June 2026 and how the stock trades relative to the average block price of ₹744.80.

For Anthem Biosciences, the deal’s immediate outcome is clear: a promoter exit, lower promoter group ownership, and a wider institutional investor base that includes major global and Indian names. Any further developments will hinge on subsequent exchange filings and future disclosures linked to shareholding and corporate actions.